NCT05959239Available不适用
Expanded Access With TB006 Treatment in Adults With Alzheimer's Disease and Related Dementias
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.
详细描述
A participant's physician who is interested in participating in this program will need to go to the company's website for further information and application forms.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisALSLou Gehrig DiseaseLou Gehrig's DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral SclerosisNCT03537807Biohaven Pharmaceuticals, Inc.
Approved For Marketing
不适用
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseGraves' OrbitopathyThyroid Eye DiseaseNCT04040894Amgen
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.
No Longer Available
不适用
Tazemetostat Expanded Access Program for Adults With Epithelioid SarcomaEpithelioid SarcomaNCT04225429Epizyme, Inc.
Available
不适用
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221GBMGlioblastoma MultiformeNCT02146066Northwest Biotherapeutics